Literature DB >> 16505435

Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.

William R Jarnagin1, David S Klimstra, Michael Hezel, Mithat Gonen, Yuman Fong, Kevin Roggin, Karina Cymes, Ronald P DeMatteo, Michael D'Angelica, Leslie H Blumgart, Bhuvanesh Singh.   

Abstract

PURPOSE: Biliary tract adenocarcinomas (BTAs), although anatomically related, arise through ill-defined and possibly different location-related pathogenetic pathways. This clinicopathologic study characterizes differences in cell cycle-regulatory protein expression across the spectrum of BTA.
METHODS: Tissue microarrays were prepared from paraffin-embedded surgical specimens with triplicate cores of BTA and benign tissue. Immunohistochemical expression of p53, cyclin D1, p21, Bcl2, p27, Mdm2, and Ki-67 was assessed, and the results were correlated with pathologic variables and survival. Hierarchical clustering was used to partition the data based on protein expression, and then the data were analyzed according to anatomic location.
RESULTS: Tissue from 128 surgical patients (1992 to 2002) was obtained. Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar cholangiocarcinoma (Hilar; n = 54), gallbladder (GB; n = 32), and distal bile duct (Distal; n = 19). p27 expression decreased progressively from proximal to distal in the biliary tree and correlated with location-related differences in outcome; cyclin D1 and Bcl2 overexpression also varied according to anatomic site. Aberrant p53 staining and cyclin D1 overexpression were lower in papillary tumors compared with the more common sclerosing tumors. The expression profiles of GB and Hilar were more similar to each other than either was to IH or Distal (86% clustering in the first partition). After an R0 resection, overexpression of Mdm2 (P = .0062) and absent p27 expression (P = .0165) independently predicted poor outcome.
CONCLUSION: BTAs differentially express cell cycle-regulatory proteins based on tumor location and morphology. Prognostic roles were identified for Mdm2 and p27. Overlap in the pathogenesis of GB and Hilar tumors was suggested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505435     DOI: 10.1200/JCO.2005.04.6631

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  31 in total

1.  Immunohistochemically detected expression of Skp2, p27 kip1, and p-p27 (Thr187) in patients with cholangiocarcinoma.

Authors:  Jian Luo; Yi Zhou; Bing Wang; Qiang Li; Yongjun Chen; Hongzhen Lan
Journal:  Tumour Biol       Date:  2015-02-09

2.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

3.  Biliary tract: Is there a role for neoadjuvant and adjuvant therapy in biliary cancer?

Authors:  William R Jarnagin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-25       Impact factor: 46.802

Review 4.  Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  A T Ruys; B E van Beem; M R W Engelbrecht; S Bipat; J Stoker; T M Van Gulik
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

5.  SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

Authors:  Anthony B El-Khoueiry; Cathryn J Rankin; Edgar Ben-Josef; Heinz-Josef Lenz; Philip J Gold; R Darryl Hamilton; Rangaswamy Govindarajan; Cathy Eng; Charles D Blanke
Journal:  Invest New Drugs       Date:  2011-07-12       Impact factor: 3.850

6.  Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions.

Authors:  Peter J Allen; Anne S Reiner; Mithat Gonen; David K Klimstra; Leslie H Blumgart; Murray F Brennan; Michael D'Angelica; Ronald Dematteo; Yuman Fong; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

7.  Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.

Authors:  Hye Sung Won; Myung Ah Lee; Eun-Seon Chung; Dong-Goo Kim; Young Kyoung You; Tae Ho Hong; In-Seok Lee
Journal:  BMC Cancer       Date:  2010-10-19       Impact factor: 4.430

Review 8.  Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs.

Authors:  Monique Stutes; Steven Tran; Sharon DeMorrow
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

9.  Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression.

Authors:  Jean M Butte; Javiera Torres; Emanuela F Veras; Kenichi Matsuo; Mithat Gönen; Michael I D'Angelica; Enrique Waugh; Manuel Meneses; Yoshiyaki Inayama; Yuman Fong; Ronald P Dematteo; Hernan De La Fuente; Itaru Endo; David S Klimstra; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2012-12-01       Impact factor: 5.344

10.  Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.

Authors:  A D Wagner; P Buechner-Steudel; M Moehler; H Schmalenberg; R Behrens; J Fahlke; A Wein; S Behl; O Kuss; G Kleber; W E Fleig
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.